Imara M&A

ELVN-001 Has a Differentiated and Attractive Profile for CML KCL-22 (BCR-ABLwt) cytotox IC50 (50% human serum) KCL-22 (BCR-ABLT3151) cytotox IC50 (50% human serum) K-562 (BCR-ABLwt) cytotox IC50 (50% human serum) K-562 pCRKL IC50 (100% human serum) HL-60 cytotox IC50 (10% FBS) Human Hepatocyte stability, extraction ratio Plasma Protein Binding (% unbound) CYPS (% inhibition @ 10 μM) hERG IC50 BCRP Substrate ● Asciminib 7 nM >1,150 nM 101 nM ΝΑ 12,200 nM ● 60 ~2 All < 50% 25 μΜ Yes Ponatinib 1 nM 14 nM 4 nM 36 nM 366 nM 62 <1 All < 50% 2.3 μM Yes Nilotinib 90 nM > 10,000 nM 228 nM 1,080 nM 5,050 nM 62 < 1 2C8, 2C9, 3A4, 2C19 > 50% 0.13 μΜ Yes ELVN-001 19 nM 131 nM 65 nM 112 nM 3,550 nM 0 40 All < 50% > 30 μη No Good potency in the presence of human serum against native BCR-ABL and T3151 (smaller potency shift compared to ponatinib & asciminib) Designed for safe and flexible use including reduced risk of DDIs, appropriate for a chronic disease setting • Good predicted human PK will enable maximal target coverage through the full dosing window Strong correlation to MMR in humans DDI = Drug-drug interaction Note: IC values represent an average derived from multiple runs internally with a minimum of two independent experiments. ADMET data were generated internally or obtained from literature including NDAs. Results of a head-to-head comparison may differ from those set forth herein. BCRP may play a role in off-target resistance 27

View entire presentation